HC Wainwright Issues Optimistic Forecast for ZNTL Earnings

Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) – Analysts at HC Wainwright upped their FY2025 earnings per share estimates for shares of Zentalis Pharmaceuticals in a research report issued on Tuesday, November 11th. HC Wainwright analyst A. Maldonado now forecasts that the company will earn ($1.78) per share for the year, up from their prior forecast of ($1.85). HC Wainwright has a “Strong-Buy” rating on the stock. The consensus estimate for Zentalis Pharmaceuticals’ current full-year earnings is ($2.42) per share. HC Wainwright also issued estimates for Zentalis Pharmaceuticals’ Q4 2025 earnings at ($0.37) EPS and FY2026 earnings at ($1.76) EPS.

ZNTL has been the subject of a number of other reports. Morgan Stanley dropped their target price on shares of Zentalis Pharmaceuticals from $8.00 to $4.00 and set an “equal weight” rating for the company in a research note on Wednesday. Leerink Partners reissued a “market perform” rating and issued a $2.00 price target on shares of Zentalis Pharmaceuticals in a report on Tuesday. Wedbush reaffirmed a “neutral” rating and set a $4.00 price objective on shares of Zentalis Pharmaceuticals in a report on Tuesday. Wells Fargo & Company decreased their price objective on Zentalis Pharmaceuticals from $6.00 to $5.00 and set an “equal weight” rating on the stock in a research report on Thursday, August 7th. Finally, Weiss Ratings restated a “sell (e+)” rating on shares of Zentalis Pharmaceuticals in a research report on Wednesday, October 8th. One analyst has rated the stock with a Strong Buy rating, one has issued a Buy rating, five have issued a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, the company currently has a consensus rating of “Hold” and a consensus price target of $5.03.

Zentalis Pharmaceuticals Stock Down 4.3%

Shares of NASDAQ ZNTL opened at $1.34 on Thursday. Zentalis Pharmaceuticals has a 12-month low of $1.01 and a 12-month high of $4.44. The firm’s 50-day simple moving average is $1.54 and its 200 day simple moving average is $1.45. The company has a market cap of $96.66 million, a price-to-earnings ratio of -0.65 and a beta of 1.87.

Zentalis Pharmaceuticals (NASDAQ:ZNTL) last announced its earnings results on Monday, November 10th. The company reported ($0.37) EPS for the quarter, topping the consensus estimate of ($0.49) by $0.12.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently bought and sold shares of the company. Cerity Partners LLC raised its holdings in Zentalis Pharmaceuticals by 58.7% in the first quarter. Cerity Partners LLC now owns 20,501 shares of the company’s stock worth $33,000 after purchasing an additional 7,579 shares during the period. SG Americas Securities LLC lifted its holdings in shares of Zentalis Pharmaceuticals by 35.3% during the 3rd quarter. SG Americas Securities LLC now owns 31,579 shares of the company’s stock valued at $48,000 after purchasing an additional 8,236 shares in the last quarter. State of Wyoming grew its position in shares of Zentalis Pharmaceuticals by 30.1% in the 1st quarter. State of Wyoming now owns 45,176 shares of the company’s stock valued at $72,000 after purchasing an additional 10,460 shares during the period. American Century Companies Inc. raised its holdings in Zentalis Pharmaceuticals by 46.2% during the 1st quarter. American Century Companies Inc. now owns 46,900 shares of the company’s stock worth $75,000 after buying an additional 14,816 shares during the period. Finally, Connor Clark & Lunn Investment Management Ltd. raised its holdings in Zentalis Pharmaceuticals by 4.7% during the 1st quarter. Connor Clark & Lunn Investment Management Ltd. now owns 361,236 shares of the company’s stock worth $574,000 after buying an additional 16,197 shares during the period.

Zentalis Pharmaceuticals Company Profile

Zentalis Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers. Its products candidatures include the ZN-c3, an inhibitor of WEE1, a protein tyrosine kinase for the treatment of inhibitor for advanced solid tumors and hematological malignancies; in Phase 2 clinical trial as a monotherapy for the treatment of uterine serous carcinoma indications; Phase 2 clinical trial in Cyclin E1 driven high-grade serous ovarian cancer, fallopian tube, or primary peritoneal cancer; Phase 1/2 clinical trial in combination with PARPi for platinum-resistant ovarian cancer; Phase 1b clinical trial in combination with chemotherapy in platinum-resistant ovarian, and peritoneal or fallopian tube cancer; Phase 1/2 clinical trial in combination with chemotherapy in relapsed or refractory osteosarcoma; Phase 1/2 clinical trial with encorafenib and cetuximab for mutant metastatic colorectal cancer; and Phase 1/2 clinical trial in combination with chemotherapy in pancreatic cancer.